244 results on '"Liakouli, V."'
Search Results
2. AB1248 DEVELOPMENT OF A CORE DOMAIN SET FOR NAILFOLD CAPILLAROSCOPY REPORTING: AN EVIDENCE-BASED CONSENSUS STUDY
3. AB0470 EFFECT OF TOFACITINIB IN MODULATING PLATELET FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS
4. H‐ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome
5. The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Stillʼs disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pathogenesis
6. Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients
7. The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus
8. Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy
9. THU0073 THE ANTI-ANGIOGENIC ROLE OF TOFACITINIB DURING EXPERIMENTAL MODEL OF ARTHRITIS.
10. THU0148 EFFICACY OF IL-1 INHIBITION ON RHEUMATOID ARTHRITIS AND TYPE 2 DIABETES, LONG-TERM FINDINGS FROM TRACK STUDY, A MULTICENTRE, OPEN-LABEL, RANDOMISED CONTROLLED TRIAL
11. The −670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis
12. Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis
13. The -670G> A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis
14. The Vessels Contribute to Fibrosis in Systemic Sclerosis
15. Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis
16. association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome
17. Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients
18. Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis
19. CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS
20. Association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary sjÖgren's syndrome
21. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management
22. SCLERODERMA FIBROBLASTS SUPPRESS ANGIOGENESIS VIA TGF-beta/CAVEOLIN-DEPENDENT SECRETION OF PIGMENTED EPITHELIUM DERIVED FACTOR: TGF-beta RECEPTOR INHIBITORS AS A NOVEL THERAPEUTIC TARGET FOR THE TREATMENT OF SCLERODERMA
23. Use of Rituximab in the Management of Sjögren’s Syndrome
24. FRI0437 Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from SSC Patients Induces an Anti Angiogenetic Effect, when Co-Cultured with Endothelial Cells
25. Macitentan inhibits the transforming growth factor-βprofibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts
26. Decreased expression of angiopoietin 1 on perivascular mesenchymalstemcells from SSc patients induces an anti angiogenic effect, when co-cultured with endothelial cells
27. Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case–control study.
28. FRI0414 Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of systemic sclerosis
29. SAT0641 Performance and agreement of different operators and histological techniques for the assessment of germinal centres in minor salivary glands in primary sjÖgren’s syndrome
30. H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome
31. AB0226 Caveolin-1 orchestrates vascular endothelial growth factor (VEGF) signaling control of angiogenesis during systemic sclerosis (SSC)
32. AB0248 Epidermal growth factor-like domain 7 (EGFL7) in skin of systemic sclerosis
33. SAT0191 Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with sjogren's syndrome
34. Potential of stem cells in the treatment of rheumatic didease
35. AB0244 Senescent bone marrow mesenchymal stem cells (BM-MSCS) preserve their immune-regulatory effect on t cells during systemic sclerosis (SSC)
36. Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease
37. Pigment epithelium derived factor secreted by ssc fibroblasts inhibits angio and vasculogenesis in vitro
38. SAT0313 Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients
39. SAT0284 Association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary sjÖgren's syndrome
40. FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome
41. Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI)
42. Pigment Epithelium Derived Factor Secreted By Activated Fibroblasts Can Contribute To Impaired Angio and Vasculogenesis In Scleroderma
43. Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with sjogren’s syndrome
44. Senescent bone marrow mesenchymal stem cells (BM-MSCS) preserve their immune-regulatory effect on t cells during systemic sclerosis (SSC)
45. SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC
46. VASCULAR SMOOTH MUSCLE CELLS (SMC) PROGENITORS: NEW PLAYERS IN SYSTEMIC SCLEROSIS (SSC) DEFECTIVE VESSEL REGENERATION
47. Interleukin-33 and its receptor st2 may serve as 'alarmin' system of the progressing damage to the skin and visceral organs of systemic sclerosis (ssc) patients
48. Association of FASG670A gene polymorphism with systemic sclerosis
49. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications
50. Differential expression of SDF-1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implication
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.